Kymera Therapeutics, Inc. (KYMR)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 34 | 73 | 47 | 79 | 47 | 39 | 105 | 105 |
| Operating profit | $m | -349 | -350 | ||||||
| Net profit | $m | -46 | -100 | -155 | -147 | -224 | -311 | -300 | -314 |
| EPS reported | $ | -3.69 | -3.25 | ||||||
| Operating cashflow per share | $ | -2.76 | -2.41 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | -2.78 | -2.42 | ||||||
| Free cash flow | $m | -234 | -238 | ||||||
| Net debt | $m | -835 | -687 | ||||||
| Book value equity | $m | 1,580 | 1,509 | ||||||
| Book value per share | $ | 18.72 | 15.37 | ||||||
| Number of shares | m | 84.39 | 98.18 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.16 | 4.35 | ||||||
| P/S LTM | x | 167.51 | 62.54 | ||||||
| P/FCF LTM | x | -28.02 | -27.60 | ||||||
| EV/EBITDA LTM | x | -20.76 | -21.49 | ||||||
| EV/Sales LTM | x | 160.50 | 91.57 | ||||||
| Earnings Yield LTM | % | -4.74% | -2.60% | ||||||
| FCF Yield | % | -3.57% | -3.62% | ||||||
| Quality | |||||||||
| ROE | % | -19.71% | -21.50% | ||||||
| ROIC | % | -20.88% | -22.14% | ||||||
| Operating margin | % | -8.91% | -3.34% | ||||||
| Gross margin | % | +100.00% | +1.02% | ||||||
| FCF/Sales | % | -597.81% | -226.65% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -16.72% | +123.04% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.85 | -2.89 | ||||||
| Net Debt/EBITDA | x | 0.91 | 0.14 | ||||||
| EBIT/Net interest | x | -1,403.21 | -1,659.61 | ||||||
| Net debt/market cap | % | +0.21% | 0.00% | ||||||
| Net debt/Equity | x | -0.53 | -0.46 | ||||||
| Gross debt/equity | x | 0.05 | 0.05 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kymera Therapeutics, Inc. (KYMR)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free